BiotechFinances
TOP LINE

GenoSafe Secures the Essential CLIA Certification

May 19, 2026

"Two or three years ago, CLIA certification was a 'nice to have.' It's become a must have" - ALAIN LAMPROYE, CEO of GenoSafe

0:00 / 0:00
Log in to listen
Audio generated by artificial intelligence. Learn more
Translated by artificial intelligence from the original French version. Learn more

The French CRO specialized, among other things, in analyses for gene therapies can now analyze clinical samples coming from across the Atlantic.

GenoSafe, a CRO originating from the AFM-Téléthon ecosystem, is developing its international positioning. Founded in 2003 and owned by a holding company bringing together AFM, Généthon and the Centre d’étude des cellules souches (CECS), the company is moving up a notch by obtaining CLIA (Clinical Laboratory Improvement Amendments) certification, allowing it to work more broadly with U.S. stakehold...

Written byRédaction BTFBiotechFinances

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.

Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.

Subscribe

Read more...

This is a standard plan article, subscribe to access the full content